BiotechTV - News

She highlights the company's next generation EGFR, which is in the clinic and reported early stage data at World Lung today, and she describes her goal with the company's Pan-KRAS inhibitor, which is still preclinical.

CEO Paul Peter Tak walks us through how the data has settled, and the steps the company needs to take before officially filing the BLA in Q4. Plus, an update on lung cancer.

He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026.

Founder & CEO Niels Riedemann describes what he believes was lacking in design for the competitor, avacopan, which has been pulled from the market in many geographies and is currently in contention at FDA, and how izicopan was built to be different. Now InflaRx needs to prove this to investors and regulators of this.

Pascal Prigent describes the test, which can be used both do diagnose patients and to monitor them. On the therapeutics side, he also discusses IQIRVO, which is marketed by Ipsen, and GENFIT's R&D work in oncology and liver failure.

Co-Founder and CEO Ben Oakes describes the difference between Scribe's approach and the first generation of CRISPR technologies. He then discusses the PCSK9 program, which harnesses epigenetic silencing, and preclinical work on Lp(a) and APOC3.

CEO Chris Peetz describes the vision for the company, and its acquisition of Bluejay, which will have phase three readouts both this quarter and next. Plus, his explanation of discussions with FDA on volixibat, and more phase 3 data that is scheduled this year on LIVMARLI.

CEO Allan Rein describes the proof of concept Prime has achieved with two patients in Chronic Granulomatous Disease, and discusses the companies plans in Wilson's Disease, Alpha-1 Antitrypsin Deficiency, and Cystic Fibrosis.

He discusses the financing dynamics of the biotech market currently, and comments on whether generalist investors are starting to participate in the sector again.

Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year.

OV329, the GABA-AT inhibitor, will have photosensitivity data over the coming months while OV4071, the KCC2, will start a ketamine challenge study by the end of the year that should give visibility to a host of important biomarkers to better understand its profile.

He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector.

CEO Jonathan Dickinson explains the rationale for the Sobi deal and what it means for the development of lacutamab. Plus, preparing for the monalizumab readout and why Innate believes its Nectin 4 is well differentiated and compelling.

Co-Founder & CEO Jennifer Good shares her take on recent clinical disappointments in the chronic cough space and describes how Trevi's therapy, Haduvio, is different. Plus, an overview of the clinical timelines.

Founder and CEO Amit Etkin describes the independent academic work that has been published on this and explains how ALTO-207, which is a combination of pramipexole and ondansetron, appears to have a more tolerable profile. Plus, an update on two other key programs

CEO Riad Sherif describes the phase 2 data Oculis delivered in optic neuritis with privosegtor last year and he previews data the company will have soon for licaminlamab in dry eye.

It also announced that the three lead programs will go after small cell lung cancer, ovarian, and hepatocellular carcinoma, though it did not disclose specific targets.

The work could help guide drug discovery and development by revealing how disease disrupts cells.

Co-Founder and CEO Alex Aravanis discusses the need for improved treatments in the obesity space and why he thinks Moonwalk's RNAi platform is an ideal approach.

Co-Founders Austin Draycott and Cole Lewis, describe the type of work they are doing (the lead program targets hepatocellular carcinoma) and the investors that participated in the financing, which include 4BIO Capital, AbbVie Ventures, Lilly, and Boehringer Ingelheim Venture Fund.